Photocure ASA
OSE:PHO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
48.05
70.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Photocure ASA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | NO |
Market Cap | 1.3B NOK |
Net Margin |
3%
|
Country | JP |
Market Cap | 776 550.9T JPY |
Net Margin |
-79%
|
Country | US |
Market Cap | 749.7B USD |
Net Margin |
20%
|
Country | UK |
Market Cap | 440.4B GBP |
Net Margin |
-4%
|
Country | DK |
Market Cap | 3.4T DKK |
Net Margin |
35%
|
Country | US |
Market Cap | 372B USD |
Net Margin |
17%
|
Country | US |
Market Cap | 257.3B USD |
Net Margin |
19%
|
Country | CH |
Market Cap | 200.4B CHF |
Net Margin |
20%
|
Country | UK |
Market Cap | 162.7B GBP |
Net Margin |
13%
|
Country | CH |
Market Cap | 179.9B CHF |
Net Margin |
35%
|
Country | US |
Market Cap | 146B USD |
Net Margin |
7%
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Photocure ASA's most recent financial statements, the company has Net Margin of 2.5%.